MiMedx Group, Inc

MiMedx develops placental tissue allografts for various healthcare sectors. The company uses its patented PURION process to retain biological properties and regulatory proteins. Products include EpiFix, AmnioFix, EpiCord, and AmnioCord for wound care, burn, and surgical recovery. These products are sold through direct sales force, independent agents, and distributors in the US. MiMedx was incorporated in 2011 and is headquartered in Marietta, Georgia. The company processes placental tissues using aseptic techniques and terminal sterilization. Its products have applications in wound care, burn, and surgical sectors of healthcare.

Overview

Sector

Biotechnology

Target Price

4.6 USD

Current Price

6.4 USD

Potential

-29%

Strengths

The company has high returns. ROIC (31.23%) is higher than the sector mean (6.02%).
EV/EBIT (15.47) is lower than the sector mean.
Price to free cash flow (15.30) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -31.90%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.

Key Financial Data

Indicator	Value
PER	22.2
EV/EBITDA	13.2
Price/Free Cash Flow'	14.6
ROIC	31.2%
Net Debt/EBITDA	100.0